Primary (congenital) insufficiency of carnitine; secondary insufficiency of carnitine; cardiomyopathy.
Composition and form of release
The main active ingredient of the drug is levocarnitine.
The auxiliary substances are diluted hydrochloric acid and water for injection.
It is produced in the form of an injection solution, poured into 10 ml ampoules.
1 ml of the drug contains 100 mg of levocarnitine.
This drug belongs to the group of amino acids or vitamin-like substances based on levocarnitine.
The main active ingredient, levocarnitine, or L-carnitine, is naturally produced independently by the human liver, kidneys and brain tissue, using amino acids such as lysine and methionine, as well as iron and ascorbic acid preparations.
Levocarnitine is the main cofactor in the metabolism of fatty acids in the muscles of the heart, skeleton and liver, therefore it is recommended for athletes. Plays important roles in other metabolic processes of the body, increases concentration.
It is able to remove metabolites and toxins from the cytoplasm, improves metabolism, including in hyperthyroidism. As a result, it helps to increase efficiency, accelerate growth, and increase muscle mass.
Due to the presence of levocarnitine, symptoms of both physical and mental stress are reduced, and it has neuroprotective, hepatoprotective and cardioprotective effects.
Reduces ischemia of the heart muscle, the amount of cholesterol in the blood. It has the property of stimulating the immune system of cells, helps to eliminate functional disorders of the nervous system in patients with alcoholism, with withdrawal symptoms.
This drug is used to treat:
- primary (congenital) carnitine deficiency;
- secondary deficiency of carnitine caused by congenital metabolic disorders.
It is also prescribed for suspected secondary carnitine deficiency in patients undergoing hemodialysis for:
- severe persistent muscle spasms and / or hypotensive episodes during dialysis;
- energy deficiency, which leads to a significant negative impact on the quality of life;
- muscle weakness and / or myopathy;
- anemia that does not respond to erythropoietin treatment or requires high doses of erythropoietin;
- loss of muscle mass.
Not applicable if the patient has hypersensitivity (allergy) to one of the components that make up the drug.
Application during pregnancy and lactation
Not used for the treatment of pregnant women (except in cases of absolute necessity).
If there is a need to take this drug, then lactation (breastfeeding) should be suspended during treatment.
Method of administration and dosage
The dosage and duration of treatment with Steatel is prescribed by the attending physician on an individual basis. The required dose is determined depending on the specificity of metabolic disorders and the severity of the manifestations of the disease.
The drug is administered intravenously, in a stream, slowly, over 2-3 minutes.
In the case of acute decompensation, the recommended dose is up to 100 mg / kg per day in 3-4 injections. If necessary, the introduction of higher doses is allowed. It should be borne in mind that this may increase side effects, including diarrhea.
When used for secondary carnitine deficiency in patients undergoing hemodialysis, the level of carnitine in the blood plasma should be checked before dosing is prescribed.
If the dosage is set at 20 mg per 1 kg of body weight, then it should be administered intravenously, jet, at the end of each dialysis session.
The normalization of the carnitine content in muscle tissue and cardiomyocytes occurs approximately 3 months after reaching the normal concentration of carnitine in the blood plasma. If the administration of carnitine is stopped, its level will certainly begin to decline again. The need for a repeated course of treatment is determined by quantifying carnitine in blood plasma at regular intervals and by monitoring the patient’s condition.
When carrying out hemodialysis, the drug is used as a maintenance therapy, 1 gram of levocarnitine per day, orally.
On the day of dialysis, the drug is administered intravenously at a dose of 1 g, immediately after the end of the hemodialysis session.
In the course of treatment, tolerance and clinical response should be assessed. Control is carried out using a biochemical blood test, measuring the concentration of carnitine in the blood plasma, the general clinical condition of the patient.
There are no cases of drug overdose at the moment.
If taken too much, diarrhea is possible. Treatment of symptoms, gastric lavage, and intake of enterosorbents is recommended.
Therapy with this drug can cause side reactions in the form of:
- allergic reactions;
- dyspeptic disorders;
- pain in the epigastrium;
- nausea, vomiting;
- may cause stomach reaction as a laxative;
- seizures, convulsive seizures (in those suffering from seizures – more frequent seizures).
If you have any unusual side effects as a result of taking this drug, you should consult your doctor about possible changes in the treatment regimen.
Storage conditions and periods
The shelf life of the drug is no more than 3 years from the production date indicated on the package.
Store in a dry place, out of reach of children, at a temperature not lower than 25 ° C.